Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
A preliminary observational study by the investigators has shown that tadalafil, a selective
phosphodiesterase-5 inhibitor (PDE-5) decreases pulmonary vascular resistance(PVR) in
patients of eisenmenger syndrome (ES) resulting in increase in pulmonary blood flow (Qp),
systemic oxygen saturation (SaO2), functional class and exercise capacity. The aim of this
placebo controlled trial was to assess the effect of the drug on exercise capacity and
functional class compared to placebo.